Coronary Artery Disease

A glycoprotein VI inhibitor (Revacept, AdvanceCor) as alternative platelet inhibition strategy during PCI for CAD.

Recently, there has been renewed interest in the treatment of higher-risk patients undergoing PCI for complex CAD. Novel techniques and equipment have expanded operators’ ability to treat patients with increasingly complicated lesion types.

Among patients with coronary artery lesions, medically treated vessels with abnormal fractional flow reserve but intact coronary flow reserve did not have noninferior outcomes vs. vessels with normal FFR and coronary flow reserve.

Among patients with diabetes, risk for MI was elevated in those with CAD, but not in those without it, according to a poster presented at the European Society of Cardiology Congress.

PET perfusion and flow assessment may guide revascularization strategies for patients with CAD, according to a presentation at the Scientific Session and Exhibition of the American Society of Nuclear Cardiology.

Psychiatric disorders were common among cardiac outpatients in the Middle East, according to results of a cross-sectional study published in Psychiatric Annals.

Among patients with peripheral artery disease who underwent revascularization, those with concomitant clinical evidence of CAD received greater absolute benefit of reduced risk for MACE from taking low-dose rivaroxaban than those with PAD without CAD.

A higher dose of a glycoprotein VI inhibitor in patients with CAD who underwent PCI resulted in more pronounced platelet inhibition without increasing bleeding risk, researchers found in the ISAR PLASTER trial.

Type 2 diabetes has an established causal association to CAD, but researchers observed no apparent genetic link between diabetes and risk for CAD, according to a study published in Circulation: Genomic and Precision Medicine.

Corticosteroids with standard treatment for patients with Kawasaki disease reduced the risk for coronary artery abnormalities and treatment failure, researchers found.